Market Overview
The global AAV Vector Transfection Kits market was valued at USD 94.8 million in 2024 and is projected to reach USD 515 million by 2031, exhibiting a CAGR of 28.0% during the forecast period. This rapid growth is primarily driven by the increasing number of gene therapy clinical trials and the subsequent demand for efficient viral vector production systems. With over 2,000 gene therapy clinical trials ongoing globally as of early 2024, the demand for high-quality transfection reagents continues to accelerate.
Market size
USD 94.8 million in 2024
2032
USD 94.8 million in 2024
CAGR of 28.0%
Adeno-associated Virus (AAV) Vectors
Lentiviral Vectors
Adenoviral Vectors
Retroviral Vectors
Adeno-associated Virus vectors dominate due to their superior safety profile and long-term gene expression stability, making them the preferred choice for chronic disease treatments and long-term gene therapy applications.
By Application
Gene Therapy Development
Cell Line Engineering
Biopharmaceutical Production
Academic Research
Clinical Applications
Gene therapy development represents the largest segment due to the increasing number of clinical trials and the growing pipeline of gene-based therapeutics requiring efficient and scalable transfection solutions.
https://www.24lifesciences.com
Our Key Players
Thermo Fisher Scientific Inc. (US)
Merck KGaA (Germany)
Takara Bio Inc. (Japan)
Promega Corporation (US)
Fujifilm Holdings Corporation (Japan)
Takara Bio Inc. (Japan)
Roche Diagnostics (Switzerland)
